Perceptions and experiences of patients receiving oral chemotherapy

Clinical Journal of Oncology Nursing

Volumn 14, Issue 4, 2010, Pages 447-453

  Simchowitz, Brett ^a   Shiman, Lawrence ^b   Spencer, Justin ^b   Brouillard, Daniela ^b   Gross, Anne ^b   Connor, Maureen ^b   Weingart, Saul N ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CHILD; DRUG MONITORING; DRUG SELF ADMINISTRATION; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; MIDDLE AGED; NEOPLASM; NURSING; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; PATIENT SATISFACTION; SAFETY; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; BOSTON; CHILD; DRUG MONITORING; FEMALE; FOCUS GROUPS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; SAFETY; SELF ADMINISTRATION;

EID: 79952114811     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/10.CJON.447-453     Document Type: Article

References (19)

1. Aisner, J. (2007). Overview of the changing paradigm in cancer treatment: Oral chemotherapy. American Journal of Health-System Pharmacy, 64(9, Suppl. 5), S4-S7. doi: 10.2146/ajhp070035
2. Birner, A. (2003). Safe administration of oral chemotherapy. Clinical Journal of Oncology Nursing, 7, 158-162. doi: 10.1188/03.CJON.158-162
3. Borner, M., Scheithauer, W., Twelves, C., Maroun, J., & Wilke, H. (2001). Answering patients' needs: Oral alternatives to intravenous therapy. Oncologist, 6(Suppl. 4), 12-16. Retrieved from http://theoncologist.alphamedpress.org/cgi/content/full/6/suppl_4/12
4. Borner, M.M., Schoffski, P., de Wit, R., Caponigro, F., Comella, G., Sulkes, A.,. Fumoleau, P. (2002). Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. European Journal of Cancer, 38, 349-358.
5. Cassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M.,. Capecitabine Colorectal Cancer Study Group. (2002). First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology, 13, 566-575. doi: 10.1093/annonc/mdf089
6. Depierre, A., Freyer, G., Jassem, J., Orfeuvre, H., Ramlau, R., Lemarie E.,. Trillet-Lenoir, V. (2001). Oral vinorelbine: Feasibility and safety profile. Annals of Oncology, 12, 1677-1681. Retrieved from http://annonc.oxfordjournals.org/content/12/12/1677.long
7. Douillard, J.Y., Hoff, P.M., Skillings, J.R., Eisenberg, P., Davidson, N., Harper, P.,. Benner, S.E. (2002). Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology, 20, 3605-3616. doi: 10.1200/JCO.2002.04.123
8. Hoff, P.M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M.,. Wong, R. (2001). Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. Journal of Clinical Oncology, 19, 2282-2292. Retrieved from http://jco.ascopubs.org/cgi/content/full/19/8/2282
9. Lebovits, A.H., Strain, J.J., Schleifer, S.J., Tanaka, J.S., Bhardwaj, S., & Messe, M.R. (1990). Patient noncompliance with self-administered chemotherapy. Cancer, 65, 17-22.
10. Levine, A.M., Richardson, J.L., Marks, G., Chan, K., Graham, J., Selser, J.N.,. Johnson, C.A. (1987). Compliance with oral drug therapy in patients with hematologic malignancy. Journal of Clinical Oncology, 5, 1469-1476.
11. Liu, G., Franssen, E., Fitch, M.I., & Warner, E. (1997). Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology, 15, 110-115.
12. Love, R.R., Cameron, L., Connell, B.L., & Leventhal, H. (1991). Symptoms associated with tamoxifen treatment in postmenopausal women. Archives of Internal Medicine, 151, 1842-1847.
13. Miles, M.B., & Huberman, A.M. (1994). Qualitative data analysis: An expanded sourcebook (2nd ed.). Thousand Oaks, CA: Sage.
14. Partridge, A.H., Avorn, J., Wang, P.S., & Winer, E.P. (2002). Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute, 94, 652-661. doi: 10.1093/jnci/94.9.652
15. Payne, S.A. (1992). A study of quality of life in cancer patients receiving palliative chemotherapy. Social Science and Medicine, 35, 1505-1509.
16. Viele, C.S. (2007). Managing oral chemotherapy: The healthcare practitioner's role. American Journal of Health-System Pharmacy, 64(9, Suppl. 5), S25-S32. doi: 10.2146/ajhp070037
17. Vinciguerra, V., Degnan, T.J., Sciortino, A., O'Connell, M., Moore, T., Brody, R.,. Carlton D. (1986). A comparative assessment of home versus hospital comprehensive treatment for advanced cancer patients. Journal of Clinical Oncology, 4, 1521-1528.
18. Weingart, S.N., Brown, E., Bach, P.B., Eng, K., Johnson, S.A., Kuzel, T.M.,. Walters, R.S. (2008). NCCN task force report: Oral chemotherapy. Journal of the National Comprehensive Cancer Network, 6(Suppl. 3), S1-S14.
19. Weingart, S.N., Flug, J., Brouillard, D., Morway, L., Partridge, A., Bartel, S.,. Connor, M. (2007). Oral chemotherapy safety practices at US cancer centres: Questionnaire survey. BMJ, 334(7590), 407. doi: 10.1136/bmj.39069.489757.55